Vantage

Clinical Insight for Your Entire Organization

Access disease-level, longitudinal, oncology patient data to inform life science research, development, and commercial strategies with Vantage.

Use Cases

Make Better Decisions Across Therapy Lifecycle

From R&D to post marketing and HEOR, Vantage helps oncology biopharma teams identify opportunities and create enterprise level strategies for specific cancer diagnoses.

Pre-Marketing

Inform R&D strategy, optimize trial design, or create an ECA to support regulatory submission.

Commercial and Post-Marketing

Conduct Phase IV and HEOR studies and optimize commercial strategy.

COTA by the Numbers

2.1M+ Cancer Patient Lives

50/50 Academic vs. Community Treatment Setting

3 Approvals Supported

9 Hematology and Solid Tumor Diagnoses

5-Year Average Follow-up

2X Higher Inclusion Percentage in ECA vs. Competitor

Quality Real-World Data for Hematologic and Solid Tumor Diagnoses

COTA’s database of patients includes longitudinal treatment and outcomes data for oncology patients including:

Heme/Onc:

Acute Lymphoblastic Leukemia

Acute Myeloid Leukemia

Chronic Lymphocytic Leukemia

Diffuse Large B Cell Lymphoma

Follicular Lymphoma

Marginal Zone Lymphoma

Multiple Myeloma

Myelodysplastic Syndrome

Small Lymphocytic Lymphoma

Mantle Cell Lymphoma

Solid Tumors:

Breast Cancer

Colon Cancer

Rectal Cancer

Gastric Cancer

Lung Cancer

Melanoma

Ovarian Cancer

Pancreatic Cancer

Prostate Cancer

Additional Support

Get the Most of Your Vantage Data with Real-World Insights and Support

Real-World Insights and Support is an optional add-on that pairs perfectly with your Vantage data. Our team of clinical experts, researchers, and statisticians will come alongside your teams to help them use the data to design studies, run analyses, and construct regulatory submission packages.

Resources

Fueling the Future of Cancer Research

Explore our collection of clinical research, recent press, podcasts, and more.

Real-world data gets high marks for feasibility in lung cancer research: A cross-industry collaboration is advancing RWD

The real world is an unpredictable place. It can be messy and confusing, full of challenges and uncertainties that have...

Light the Night: Bringing hope to patients during Blood Cancer Awareness Month

September is Blood Cancer Awareness Month, a time to bring extra attention to the more than 1.6 million people living...

COTA and Panalgo Q&A

COTA Spokesperson: C.K. Wang, Chief Medical Officer Panalgo Spokesperson: Meg Richards, PhD, MPH, Executive Director of Scientific Strategy Abbreviated answers...

Get a Better View with Vantage

Discover the power of real-world cancer data for your life science organization.

Solutions

Products

Services

About Us

Resources

Real-world data gets high marks for feasibility in lung cancer research: A cross-industry collaboration is advancing RWD

Light the Night: Bringing hope to patients during Blood Cancer Awareness Month

Vantage

Clinical Insight for Your Entire Organization

Use Cases

Make Better Decisions Across Therapy Lifecycle

Pre-Marketing

Commercial and Post-Marketing

COTA by the Numbers

2.1M+ Cancer Patient Lives

50/50 Academic vs. Community Treatment Setting

3 Approvals Supported

9 Hematology and Solid Tumor Diagnoses

5-Year Average Follow-up

2X Higher Inclusion Percentage in ECA vs. Competitor

Quality Real-World Data for Hematologic and Solid Tumor Diagnoses

Heme/Onc:

Solid Tumors:

Additional Support

Get the Most of Your Vantage Data with Real-World Insights and Support

Resources

Fueling the Future of Cancer Research

Real-world data gets high marks for feasibility in lung cancer research: A cross-industry collaboration is advancing RWD

Light the Night: Bringing hope to patients during Blood Cancer Awareness Month

COTA and Panalgo Q&A

Get a Better View with Vantage

Solutions

Products & Services

About Us

Follow Us